Literature DB >> 20579837

An exploratory study on the effects of an expectancy manipulation on chemotherapy-related nausea.

Joseph A Roscoe1, Michael O'Neill, Pascal Jean-Pierre, Charles E Heckler, Ted J Kaptchuk, Peter Bushunow, Michelle Shayne, Alissa Huston, Raman Qazi, Brian Smith.   

Abstract

CONTEXT: Previous research has shown that the effectiveness of acupressure bands in reducing chemotherapy-related nausea is related to patients' expectations of efficacy.
OBJECTIVE: To test whether an informational manipulation designed to increase expectation of efficacy regarding acupressure bands would enhance their effectiveness.
METHODS: We conducted an exploratory, four-arm, randomized clinical trial in breast cancer patients about to begin chemotherapy. All patients received acupressure bands and a relaxation CD. This report focuses on Arm 1(expectancy-neutral informational handout and CD) compared with Arm 4 (expectancy-enhancing handout and CD). Randomization was stratified according to the patient's level of certainty that she would have treatment-induced nausea (two levels: high and low). Experience of nausea and use of antiemetics were assessed with a five-day diary.
RESULTS: Our expectancy-enhancing manipulation resulted in improved control of nausea in the 26 patients with high nausea expectancies but lessened control of nausea in 27 patients having low nausea expectancies. This interaction effect (between expected nausea and intervention effectiveness) approached statistical significance for our analysis of average nausea (P=0.084) and reached statistical significance for our analysis of peak nausea (P=0.030). Patients receiving the expectancy-enhancing manipulation took fewer antiemetic pills outside the clinic (mean(enhanced)=12.6; mean(neutral)=18.5, P=0.003).
CONCLUSION: This exploratory intervention reduced antiemetic use overall and also reduced nausea in patients who had high levels of expected nausea. Interestingly, it increased nausea in patients who had low expectancies for nausea. Confirmatory research is warranted. 2010 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20579837      PMCID: PMC3156553          DOI: 10.1016/j.jpainsymman.2009.12.024

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  40 in total

1.  Drug-related information generates placebo and nocebo responses that modify the drug response.

Authors:  M A Flaten; T Simonsen; H Olsen
Journal:  Psychosom Med       Date:  1999 Mar-Apr       Impact factor: 4.312

2.  The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: a randomised controlled trial.

Authors:  Alexander Molassiotis; Hilary P Yung; Bernard M C Yam; Flora Y S Chan; T S K Mok
Journal:  Support Care Cancer       Date:  2001-12-18       Impact factor: 3.603

Review 3.  Nonspecific medication side effects and the nocebo phenomenon.

Authors:  Arthur J Barsky; Ralph Saintfort; Malcolm P Rogers; Jonathan F Borus
Journal:  JAMA       Date:  2002-02-06       Impact factor: 56.272

Review 4.  Behavioral interventions in the diagnosis, treatment and rehabilitation of children with cancer.

Authors:  K N DuHamel; W H Redd; S M Vickberg
Journal:  Acta Oncol       Date:  1999       Impact factor: 4.089

5.  Brief presurgery hypnosis reduces distress and pain in excisional breast biopsy patients.

Authors:  Guy H Montgomery; Christina R Weltz; Megan Seltz; Dana H Bovbjerg
Journal:  Int J Clin Exp Hypn       Date:  2002-01

6.  Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma.

Authors:  Joseph A Roscoe; Peter Bushunow; Gary R Morrow; Jane T Hickok; Philip J Kuebler; Andrew Jacobs; Tarit K Banerjee
Journal:  Cancer       Date:  2004-12-01       Impact factor: 6.860

7.  Relationships between patients' pre-treatment expectations of toxicities and post chemotherapy experiences.

Authors:  Ian N Olver; Anne E Taylor; Hayley S Whitford
Journal:  Psychooncology       Date:  2005-01       Impact factor: 3.894

8.  A signal detection theory analysis of the placebo effect.

Authors:  Lorraine G Allan; Shepard Siegel
Journal:  Eval Health Prof       Date:  2002-12       Impact factor: 2.651

9.  Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community.

Authors:  Jane T Hickok; Joseph A Roscoe; Gary R Morrow; David K King; James N Atkins; Tom R Fitch
Journal:  Cancer       Date:  2003-06-01       Impact factor: 6.860

10.  The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting. A University of Rochester Cancer Center Community Clinical Oncology Program multicenter study.

Authors:  Joseph A Roscoe; Gary R Morrow; Jane T Hickok; Peter Bushunow; H Irving Pierce; Patrick J Flynn; Jeffrey J Kirshner; Dennis F Moore; James N Atkins
Journal:  J Pain Symptom Manage       Date:  2003-08       Impact factor: 3.612

View more
  11 in total

1.  Positive effects of acupressure bands combined with relaxation music/instructions on patients most at risk for chemotherapy-induced nausea.

Authors:  Anita R Peoples; Eva Culakova; Charles E Heckler; Michelle Shayne; Tracey L O'Connor; Jeffrey J Kirshner; Peter W Bushunow; Gary R Morrow; Joseph A Roscoe
Journal:  Support Care Cancer       Date:  2019-03-30       Impact factor: 3.603

Review 2.  The nocebo effect and its relevance for clinical practice.

Authors:  Luana Colloca; Franklin G Miller
Journal:  Psychosom Med       Date:  2011-08-23       Impact factor: 4.312

3.  Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients.

Authors:  Sun Young Rha; Yeonhee Park; Su Kyung Song; Chung Eun Lee; Jiyeon Lee
Journal:  Support Care Cancer       Date:  2016-03-16       Impact factor: 3.603

Review 4.  Anticipatory nausea and vomiting due to chemotherapy.

Authors:  Charles Kamen; Mohamedtaki A Tejani; Kavita Chandwani; Michelle Janelsins; Anita R Peoples; Joseph A Roscoe; Gary R Morrow
Journal:  Eur J Pharmacol       Date:  2013-10-21       Impact factor: 4.432

5.  The efficiency of the acupressure in prevention of the chemotherapy-induced nausea and vomiting.

Authors:  Aslı Genç; Gulbeyaz Can; Adnan Aydiner
Journal:  Support Care Cancer       Date:  2012-06-09       Impact factor: 3.603

6.  Treatment of Nausea and Vomiting During Chemotherapy.

Authors:  Karen M Mustian; Katie Devine; Julie L Ryan; Michelle C Janelsins; Lisa K Sprod; Luke J Peppone; Grace D Candelario; Supriya G Mohile; Gary R Morrow
Journal:  US Oncol Hematol       Date:  2011

7.  An investigation of the effects of therapeutic touch plan on acute chemotherapy-induced nausea in women with breast cancer in Isfahan, Iran, 2012-2013.

Authors:  Pegah Matourypour; Zahra Zare; Valiolah Mehrzad; Amir Musarezaie; Mojtaba Dehghan; Zohre Vanaki
Journal:  J Educ Health Promot       Date:  2015-08-06

8.  Individual differences in chemotherapy-induced anticipatory nausea.

Authors:  Marcial Rodríguez
Journal:  Front Psychol       Date:  2013-08-09

9.  Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial.

Authors:  Pia von Blanckenburg; Franziska Schuricht; Ute-Susann Albert; Winfried Rief; Yvonne Nestoriuc
Journal:  BMC Cancer       Date:  2013-09-18       Impact factor: 4.430

10.  Individual Factors Contributing to Nausea in First-Time Chemotherapy Patients: A Prospective Cohort Study.

Authors:  Karin Meissner; Nicola Talsky; Elisabeth Olliges; Carmen Jacob; Oliver J Stötzer; Christoph Salat; Michael Braun; Raluca Flondor
Journal:  Front Pharmacol       Date:  2019-04-25       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.